Cited by 243Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy

Fu, Tihui, He, Qiuming, Sharma, Padmanee·2011·Cancer Research

Published version of a preprint

Open this paper in CoChat — free account

Abstract

The anti-CTL-associated antigen 4 (anti-CTLA-4) antibody ipilimumab is the first agent to show improved survival in a randomized phase III trial that enrolled patients with metastatic melanoma. Studies are ongoing to identify mechanisms that elicit clinical benefit in the setting of anti-CTLA-4 therapy. We previously reported that treated patients had an increase in the frequency of T cells expressing the inducible costimulator (ICOS) molecule, a T-cell-specific molecule that belongs to the CD28/CTLA-4/B7 immunoglobulin superfamily. ICOS and its ligand (ICOSL) have been shown to play diverse roles in T-cell responses such as mediating autoimmunity as well as enhancing the development/activity of regulatory T cells. These seemingly opposing roles have made it difficult to determine whether the ICOS/ICOSL pathway is necessary for antitumor responses. To determine whether the ICOS/ICOSL pathway might play a causal role in the antitumor effects mediated by anti-CTLA-4, we conducted studies in ICOS-sufficient and ICOS-deficient mice bearing B16/BL6 melanoma. We show that ICOS(+) T cells comprised a population of Th1 cytokine producing and tumor antigen-specific effector cells. Furthermore, in the absence of ICOS, antitumor T-cell responses elicited by anti-CTLA-4 are significantly diminished, thereby impairing tumor rejection. Our findings establish that the ICOS/ICOSL pathway is necessary for the optimal therapeutic effect of anti-CTLA-4, thus implicating this pathway as a target for future combinatorial strategies to improve the efficacy of anti-CTLA-4 therapy.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-1138

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is the prototypical coinhibitory molecule that opposes CD28mediated costimulation (3-5).”
Background
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The B7–CD28 superfamily
Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759
Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones
Harding, F., McArthur, J. G., Gross, J. A., Raulet, D. H., & Allison, J. P. (1992) · Nature · doi:10.1038/356607a0 · Cited by 1,558
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 8×
“ICOSCD8T cells produce IFN-γ upon recognition of tumor antigen and the absence of ICOS results in diminished tumor antigen-specific T cell responses Since CD8 T cells have been shown to play a dominant role in tumor rejection in the B16/BL6 melanoma model treated with anti-CTLA-4 (7-9, 36), we investigated the impact…”
BackgroundMethodResultInfluential

Show all 48 references

Sorted by citations

The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Self-citation
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Self-citation
IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Ivashkiv, L. B. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,418
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Self-citation
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Self-citation
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Self-citation
The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC
Jin, Y., Dong, H., Xia, L., Yang, Y., Zhu, Y., Shen, Y., Zheng, H., Yao, C., Wang, Y., & Lu, S. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.007 · Cited by 573
Discovery of IDO1 Inhibitors: From Bench to Bedside
Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2285 · Cited by 571
Immune Modulation in Cancer with Antibodies
Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 523
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
Coutzac, C., Jouniaux, J.-M., Paci, A., Schmidt, J., Mallardo, D., Seck, A., Asvatourian, V., Cassard, L., Saulnier, P., Lacroix, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16079-x · Cited by 513
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D., Wu, X., & Sun, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 538
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik‐Nayak, L., Laury‐Kleintop, L. D., Metz, R. A., & Muller, A. J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 491
Dissecting the mechanisms of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0275-8 · Cited by 436
Self-citation
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis
Labadie, B. W., Bao, R., & Luke, J. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2882 · Cited by 413
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
Tang, K., Wu, Y., Song, Y., & Yu, B. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01080-8 · Cited by 375
Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
Hodi, F. S., Lee, S., McDermott, D. F., Rao, U. N. M., Butterfield, L. H., Tarhini, A. A., Leming, P. D., Puzanov, I. J., Shin, D., & Kirkwood, J. M. (2014) · JAMA · doi:10.1001/jama.2014.13943 · Cited by 361
Emerging targets in cancer immunotherapy
Burugu, S., Dancsok, A. R., & Nielsen, T. O. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.001 · Cited by 320
B7 family checkpoint regulators in immune regulation and disease
Ceeraz, S., Nowak, E. C., & Noelle, R. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.003 · Cited by 323
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P., & Allison, J. P. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130590 · Cited by 300
Self-citation
Second- and third-generation drugs for immuno-oncology treatment—The more the better?
Dempke, W. C. M., Fenchel, K., Uciechowski, P., & Dale, S. P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.001 · Cited by 264
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250
Cancer Metabolism: Current Understanding and Therapies
Counihan, J. L., Grossman, E. A., & Nomura, D. K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00775 · Cited by 236
Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
Srivastava, S., & Riddell, S. R. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701155 · Cited by 222
Therapy for metastatic melanoma: the past, present, and future
Finn, L. E., Markovic, S. N., & Joseph, R. W. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-23 · Cited by 224
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy
Ng Tang, D., Shen, Y., Sun, J., Wen, S., Wolchok, J. D., Yuan, J., Allison, J. P., & Sharma, P. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0020 · Cited by 203
Self-citation
Immunoregulatory functions of VISTA
Nowak, E. C., Lines, J. L., Varn, F. S., Deng, J., Sarde, A., Mabaera, R., Kuta, A., Mercier, I. L., Cheng, C., & Noelle, R. J. (2017) · Immunological Reviews · doi:10.1111/imr.12525 · Cited by 200
MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints
Wei, J., Nduom, E. K.-E., Kong, L.-Y., Hashimoto, Y., Xu, S., Gabrusiewicz, K. R., Ling, X., Huang, N., Qiao, W., Zhou, S., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov292 · Cited by 199
The role of B7 family molecules in hematologic malignancy
Greaves, P., & Gribben, J. G. (2012) · Blood · doi:10.1182/blood-2012-10-385591 · Cited by 195
Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks
Meng, L., Wu, H., Wu, J., Ding, P., He, J., Sang, M., & Liu, L. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06389-5 · Cited by 202
The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
Solinas, C., Gu‐Trantien, C., & Willard-Gallo, K. E. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000544 · Cited by 182
Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
Redmond, W. L., Linch, S. N., & Kasiewicz, M. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0031-t · Cited by 174
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Graziani, G., Tentori, L., & Navarra, P. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.002 · Cited by 166
Biomarkers associated with checkpoint inhibitors
Manson, G., Norwood, J., Marabelle, A., Kohrt, H. E. K., & Houot, R. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw181 · Cited by 166
Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential
Wang, L., Liang, Y., Zhao, C., Ma, P., Zeng, S., Ju, D., Zhao, M., Yu, M., & Shi, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02326-4 · Cited by 190
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
Coutzac, C., Adam, J., Soularue, É., Collins, M., Racine, A., Mussini, C., Boselli, L., Kamsu-Kom, N., Mateus, C., Charrier, M., et al. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx081 · Cited by 158
Dietary Lactobacillus -Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy
Kawanabe-Matsuda, H., Takeda, K., Nakamura, M., Makino, S., Karasaki, T., Kakimi, K., Nishimukai, M., Ohno, T., Omi, J., Kano, K., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0929 · Cited by 158
Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
Lesterhuis, W. J., Salmons, J., Nowak, A. K., Rozali, E. N., Khong, A., Dick, I. M., Harken, J. A., Robinson, B. W. S., & Lake, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061895 · Cited by 145
Novel targets for immune-checkpoint inhibition in cancer
Borgeaud, M., Sandoval, J. L., Obéid, M., Banna, G. L., Michielin, O. A., Addeo, A., & Friedlaender, A. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102614 · Cited by 150
The immune contexture of primary and metastatic human tumours
Giraldo, N. A., Becht, É., Remark, R., Damotte, D., Sautès‐Fridman, C., & Fridman, W. H. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.001 · Cited by 144
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer
Raval, R. R., Sharabi, A. B., Walker, A. J., Drake, C. G., & Sharma, P. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-14 · Cited by 140
Self-citation
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
Zamarin, D., Holmgaard, R., Ricca, J. M., Plitt, T., Palese, P., Sharma, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2017) · Nature Communications · doi:10.1038/ncomms14340 · Cited by 144
Self-citation
Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
Ascierto, P. A., Kalos, M. D., Schaer, D., Callahan, M. K., & Wolchok, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2982 · Cited by 141
Experimental mouse tumour models: what can be learnt about human cancer immunology?
Dranoff, G. (2011) · Nature reviews. Immunology · doi:10.1038/nri3129 · Cited by 138
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
Giacomo, A. M. D., Ascierto, P. A., Queirolo, P., Pilla, L., Ridolfi, R., Santinami, M., Testori, A., Simeone, E., Guidoboni, M., Maurichi, A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu577 · Cited by 139
Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations
Baksh, K. A., & Weber, J. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.015 · Cited by 132
Orchestrating immune check-point blockade for cancer immunotherapy in combinations
Perez‐Gracia, J. L., Labiano, S., Rodriguez-Ruiz, M. E., Sanmamed, M. F., & Melero, I. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.002 · Cited by 131
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 132
Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer
Fox, E. E., Oliver, T., Rowe, M. M., Thomas, S., Zakharia, Y., Gilman, P. B., Muller, A. J., & Prendergast, G. C. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00370 · Cited by 126
Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy
Amatore, F., Gorvel, L., & Olive, D. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1693540 · Cited by 126
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Wang, W., Yu, D., Sarnaik, A. A., Yu, B., Hall, M. S., Morelli, D., Zhang, Y., Zhao, X., & Weber, J. S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-146 · Cited by 122
Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?
Cinier, J., Hubert, M., Besson, L., Roio, A. D., Rodriguez, C., Lombardi, V., Caux, C., & Ménétrier‐Caux, C. (2021) · Cancers · doi:10.3390/cancers13081850 · Cited by 125
Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy
Geels, S. N., Moshensky, A., Sousa, R. S., Murat, C., Bustos, M. A., Walker, B. L., Singh, R., Harbour, S. N., Gutierrez, G., Hwang, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.013 · Cited by 124
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease
Achberger, S., Aldrich, W. A., Tubbs, R., Crabb, J. W., Singh, A. D., & Triozzi, P. L. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.11.018 · Cited by 114
CTLA-4 correlates with immune and clinical characteristics of glioma
Liu, F., Huang, J., Liu, X., Cheng, Q., Luo, C., & Liu, Z. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1085-6 · Cited by 115
Clinical Insights Into Novel Immune Checkpoint Inhibitors
Lee, J. B., Ha, S., & Kim, H. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.681320 · Cited by 115
Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
Liu, H., Liu, K., & Dong, Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2245 · Cited by 101
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
Bartkowiak, T., Singh, S., Yang, G., Sierra, G., Haria, D., Ai, M., Allison, J. P., Sastry, K. J., & Curran, M. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514418112 · Cited by 100
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review
Mazzarella, L., Duso, B. A., Trapani, D., Belli, C., D’Amico, P., Ferraro, E., Viale, G., & Curigliano, G. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.035 · Cited by 100
Targeting Costimulatory Molecules to Improve Antitumor Immunity
Capece, D., Verzella, D., Fischietti, M., Zazzeroni, F., & Alesse, E. (2012) · BioMed Research International · doi:10.1155/2012/926321 · Cited by 103
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
Jochéms, C., Tucker, J. A., Tsang, K.-Y., Madan, R. A., Dahut, W. L., Liewehr, D. J., Steinberg, S. M., Gulley, J. L., & Schlom, J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1524-0 · Cited by 97
Boosting Checkpoint Immunotherapy with Biomaterials
Liu, L., Pan, Y., Zhao, C., Huang, P., Chen, X. S., & Rao, L. (2023) · ACS Nano · doi:10.1021/acsnano.2c11691 · Cited by 97
Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy
Amatore, F., Gorvel, L., & Olive, D. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1444753 · Cited by 95
The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy
Lee, J., Lozano‐Ruiz, B., Yang, F. M., Fan, D. D., Shen, L., & González-Navajas, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625667 · Cited by 102
Fcγ receptors and immunomodulatory antibodies in cancer
Gálvez‐Cancino, F., Simpson, A. P., Costoya, C., Matos, I. G., Qian, D., Peggs, K. S., Litchfield, K., & Quezada, S. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00637-8 · Cited by 99
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy
Leung, J., & Suh, W. (2014) · Immune Network · doi:10.4110/in.2014.14.6.265 · Cited by 92
Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
Luke, J. J., & Hodi, F. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0391 · Cited by 84
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy
Hailemichael, Y., Woods, A. N., Fu, T., He, Q., Nielsen, M. C., Hasan, F., Roszik, J., Xiao, Z., Vianden, C., Khong, H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93303 · Cited by 81
Self-citation
ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+T cells by plasmacytoid dendritic cells
Faget, J., Sisirak, V., Blay, J., Caux, C., Bendriss‐Vermare, N., & Ménétrier‐Caux, C. (2013) · OncoImmunology · doi:10.4161/onci.23185 · Cited by 81
The expression, function, and clinical relevance of B7 family members in cancer
Seliger, B., & Quandt, D. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1293-6 · Cited by 79
HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells
Shen, H., Ojo, O. A., Ding, H., Mullen, L. J., Xing, C., Hossain, M. I., Yassin, A., Shi, V. Y., Lewis, Z., Podgórska, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53593-8 · Cited by 90
Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non–Small Cell Lung Carcinoma Tumors
Parra, E. R., Villalobos, P. A., Zhang, J., Behrens, C., Mino, B., Swisher, S. G., Sepesi, B., Weissferdt, A., Kalhor, N., Heymach, J. V., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.002 · Cited by 74
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Ascierto, P. A., Marincola, F. M., & Ribas, A. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-196 · Cited by 76
Senescence-induced endothelial phenotypes underpin immune-mediated senescence surveillancePreprint
Yin, K., Patten, D. A., Gough, S., Gonçalves, S. D. B., Chan, A. S. L., Olan, I., Cassidy, L. D., Poblocka, M., Zhu, H., Lun, A. T. L., et al. (2022) · Genes & Development · doi:10.1101/gad.349585.122 · Cited by 75
Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
Silva, D. M. D., Enserro, D. M., Mayadev, J., Skeate, J. G., Matsuo, K., Pham, H. Q., Lankes, H. A., Moxley, K. M., Ghamande, S. A., Lin, Y. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0776 · Cited by 75
Next generation immune-checkpoints for cancer therapy
Donini, C., D’Ambrosio, L., Grignani, G., Aglietta, M., & Sangiolo, D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.02.79 · Cited by 74
Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: In vitro and in vivo studies
Nikpoor, A. R., Tavakkol‐Afshari, J., Sadri, K., Jalali, S. A., & Jaafari, M. R. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.08.010 · Cited by 71
Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
Lazarus, H. M., Ragsdale, C. E., Gale, R. P., & Lyman, G. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.706186 · Cited by 72
ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy
Marinelli, O., Nabissi, M., Morelli, M. B., Torquati, L., Amantini, C., & Santoni, G. (2018) · Current Protein and Peptide Science · doi:10.2174/1389203719666180608093913 · Cited by 69
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40–Mediated Tumor Rejection
Metzger, T. C., Long, H., Potluri, S., Pertel, T., Bailey-Bucktrout, S. L., Lin, J. C.-Y., Fu, T., Sharma, P., Allison, J. P., & Feldman, R. M. R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3412 · Cited by 67
Self-citation
Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors
Rudqvist, N.-P., Charpentier, M., Lhuillier, C., Wennerberg, E., Spada, S., Sheridan, C. K., Zhou, X. K., Zhang, T., Formenti, S. C., Sims, J. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40844-3 · Cited by 68
Emerging immunotherapies for metastasis
Edwards, S. C., Hoevenaar, W. H. M., & Coffelt, S. B. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01160-5 · Cited by 62
Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing
Lemoine, J., Ruella, M., & Houot, R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1559 · Cited by 61
CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy
Chen, H., Fu, T., Suh, W., Tsavachidou, D., Wen, S., Gao, J., Tang, D. N., He, Q., Sun, J., & Sharma, P. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0155 · Cited by 59
Self-citation
Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab
Damuzzo, V., Solito, S., Pinton, L., Carrozzo, E., Valpione, S., Pigozzo, J., Arboretti, R., Chiarion‐Sileni, V., & Mandruzzato, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1249559 · Cited by 60
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 62
Microbiome bacterial influencers of host immunity and response to immunotherapy
Yousefi, Y., Baines, K. J., & Vareki, S. M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101487 · Cited by 60
ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity
Soldevilla, M. M., Villanueva, H., Meraviglia-Crivelli, D., Menon, A. P., Ruiz, M., Cebollero, J., Villalba-Esparza, M., Moreno, B., Lozano, T., Llópiz, D., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.013 · Cited by 53
T cell costimulation, checkpoint inhibitors and anti-tumor therapy
Nandi, D., Pathak, S., Verma, T., Singh, M., Chattopadhyay, A., Thakur, S., Raghavan, A., Gokhroo, A., & Vijayamahantesh, V. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-0020-2 · Cited by 58
An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Sainson, R. C. A., Thotakura, A. K., Kosmač, M., Borhis, G., Parveen, N., Kimber, R., Carvalho, J. A., Henderson, S. J., Pryke, K. L., Okell, T., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0034 · Cited by 56
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
Rowdo, F. P. M., Barón, A., Urrutia, M., & Mordoh, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00127 · Cited by 51
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity
Langdon, S., Hughes, A. M., Taylor, M. A., Kuczynski, E. A., Mele, D. A., Delpuech, O., Jarvis, L., Staniszewska, A. D., Cosulich, S. C., Carnevalli, L. S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1458810 · Cited by 52
A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer
Tuyaerts, S., Rombauts, K., Everaert, T., Nuffel, A. M. T. V., & Amant, F. C. (2019) · Frontiers in Nutrition · doi:10.3389/fnut.2018.00138 · Cited by 51
The role of CD4+ T cells in tumor and chronic viral immune responses
Xie, L., Fang, J., Yu, J., Zhang, W., He, Z., Ye, L., & Wang, H. (2023) · MedComm · doi:10.1002/mco2.390 · Cited by 54
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade
Haymaker, C., Kim, D. W., Uemura, M. I., Vence, L. M., Phillip, A., McQuail, N., Brown, P. D., Fernandez, I., Hudgens, C. W., Creasy, C. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0223 · Cited by 49
Self-citation
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner
Shi, L. Z., Goswami, S., Fu, T., Guan, B., Chen, J., Xiong, L., Zhang, J., Tang, D. N., Zhang, X., Vence, L. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0873 · Cited by 47
Self-citation
Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
Hong, M. M. Y., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14061580 · Cited by 52
Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer
Parra, E. R., Zhang, J., Jiang, M., Tamegnon, A., Pandurengan, R. K., Behrens, C., Solis, L. M., Haymaker, C., Heymach, J. V., Moran, C. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37905-y · Cited by 47
Immune checkpoint combinations from mouse to man
Ai, M., & Curran, M. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1650-8 · Cited by 45

Authors: Fu, T., He, Q., & Sharma, P.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
ORCID: Sharma, Padmanee
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2011-08-11
Volume: 71
Issue: 16
Pages: 5445-5454
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-11-1138
OpenAlex: W2141756397
Cited by: 243
References: 48
Citations by year: 2026: 4 · 2025: 9 · 2024: 15 · 2023: 25 · 2022: 19 · 2021: 23 · 2020: 19 · 2019: 14 · 2018: 20 · 2017: 16 · 2016: 14 · 2015: 17 · 2014: 13 · 2013: 21 · 2012: 11
FWCI: 7.48
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4 blockade, ipilimumab, metastatic melanoma, B16-BL6 melanoma, antitumor T-cell responses, tumor rejection, CTLA-4, regulatory T cells, autoimmunity
MeSH terms: Animals, Enzyme-Linked Immunosorbent Assay, Melanoma, Experimental, Mice, Inbred C57BL, Proteins, Antigens, CD, Lymphocytes, Tumor-Infiltrating, Mice, CTLA-4 Antigen, Inducible T-Cell Co-Stimulator Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks